CD22 and B-cell acute lymphoblastic leukemia: CD22 has been evaluated as a candidate target antigen mainly in B-cell acute lymphoblastic leukemia, but clinical trials including patients with refractory CD22+ NHL are ongoing (NCT02794961, NCT02315612).